Renal organic anion transporters (SLC22 Family): Expression, regulation, roles in toxicity, and impact on injury and disease

AAPS Journal

Volumn 15, Issue 1, 2013, Pages 53-69

  Wang, Li ^a   Sweet, Douglas H ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

kidney; nephrotoxicity; proximal tubule; solute carrier

Indexed keywords

BESTATIN; BUMETANIDE; CAFFEIC ACID; DIAZEPAM; FERULIC ACID; GABOXADOL; GALLIC ACID; GEMCABENE; GEMFIBROZIL; GENTISIC ACID; INDOMETACIN; LITHOSPERMIC ACID; LUMIRACOXIB; MERCURY; MESNA; MIANSERIN; ORGANIC ANION TRANSPORTER; PARECOXIB; PHENOL DERIVATIVE; PRAVASTATIN; PROBENECID; PROTOCATECHUIC ACID; QUINAPRIL; RIFAMPICIN; ROSMARINIC ACID; SALAZOSULFAPYRIDINE; SALVIANOLIC ACID B; SINAPIC ACID; UNINDEXED DRUG; VANILLIC ACID;

ACUTE KIDNEY FAILURE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; CHRONIC KIDNEY FAILURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COMPETITION; DRUG POTENCY; ENZYME SPECIFICITY; FOOD DRUG INTERACTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IC 50; KIDNEY INJURY; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE ABSORPTION; MERCURIALISM; NEPHROTOXICITY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN TARGETING; RENAL PROTECTION; REVIEW; UNSPECIFIED SIDE EFFECT;

ANIMALS; BIOLOGICAL TRANSPORT; HUMANS; KIDNEY; KIDNEY DISEASES; KIDNEY TUBULES, PROXIMAL; ORGANIC ANION TRANSPORTERS; PROMOTER REGIONS, GENETIC;

EID: 84871983440     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-012-9413-y     Document Type: Review

References (108)

1. He L, Vasiliou K, Nebert DW. Analysis and update of the human solute carrier (SLC) gene superfamily. Hum Genomics. 2009;3:195-206.
2. Sweet DH. Organic anion transporter (Slc22a) family members as mediators of toxicity. Toxicol Appl Pharmacol. 2005;204:198-215. (Pubitemid 40545228)
3. VanWert AL, Gionfriddo MR, Sweet DH. Organic anion transporters: discovery, pharmacology, regulation and roles in pathophysiology. Biopharm Drug Dispos. 2010;31:1-71.
4. Sweet DH. Renal organic cation and anion transport: from physiology to genes. In: McQueen CA, editor. Comprehensive toxicology, 2nd ed., vol. 7. Oxford: Elsevier; 2010. p. 23-53.
5. Tsuchida H, Anzai N, Shin HJ, Wempe MF, Jutabha P, Enomoto A, et al. Identification of a novel organic anion transporter mediating carnitine transport in mouse liver and kidney. Cell Physiol Biochem. 2010;25:511-22.
6. Ogasawara K, Terada T, Asaka J, Katsura T, Inui K. Human organic anion transporter 3 gene is regulated constitutively and inducibly via a cAMP-response element. J Pharmacol Exp Ther. 2006;319:317-22. (Pubitemid 44455138)
7. Kikuchi R, Kusuhara H, Hattori N, Kim I, Shiota K, Gonzalez FJ, et al. Regulation of tissue-specific expression of the human and mouse urate transporter 1 gene by hepatocyte nuclear factor 1 alpha/beta and DNA methylation. Mol Pharmacol. 2007;72:1619-25. (Pubitemid 350146099)
8. Saji T, Kikuchi R, Kusuhara H, Kim I, Gonzalez FJ, Sugiyama Y. Transcriptional regulation of human and mouse organic anion transporter 1 by hepatocyte nuclear factor 1 alpha/beta. J Pharmacol Exp Ther. 2008;324:784-90. (Pubitemid 351185851)
9. Kikuchi R, Kusuhara H, Hattori N, Shiota K, Kim I, Gonzalez FJ, et al. Regulation of the expression of human organic anion transporter 3 by hepatocyte nuclear factor 1alpha/beta and DNA methylation. Mol Pharmacol. 2006;70:887-96. (Pubitemid 44268446)
10. Jin L, Kikuchi R, Saji T, Kusuhara H, Sugiyama Y. Regulation of tissue-specific expression of renal organic anion transporters by hepatocyte nuclear factor 1 alpha/beta and DNA methylation. J Pharmacol Exp Ther. 2012;340:648-55.
11. Klein K, Jungst C, Mwinyi J, Stieger B, Krempler F, Patsch W, et al. The human organic anion transporter genes OAT5 and OAT7 are transactivated by hepatocyte nuclear factor-1alpha (HNF-1alpha). Mol Pharmacol. 2010;78:1079-87.
12. Ogasawara K, Terada T, Asaka J, Katsura T, Inui K. Hepatocyte nuclear factor-4{alpha} regulates the human organic anion transporter 1 gene in the kidney. Am J Physiol Renal Physiol. 2007;292:F1819-26. (Pubitemid 47105372)
13. Popowski K, Eloranta JJ, Saborowski M, Fried M, Meier PJ, Kullak-Ublick GA. The human organic anion transporter 2 gene is transactivated by hepatocyte nuclear factor-4 alpha and suppressed by bile acids. Mol Pharmacol. 2005;67:1629-38. (Pubitemid 40594162)
14. Wegner W, Burckhardt BC, Burckhardt G, Henjakovic M. Male-dominant activation of rat renal organic anion transporter 1 (Oat1) and 3 (Oat3) expression by transcription factor BCL6. PLoS One. 2012;7:e35556.
15. Duan P, Li S, You G. Angiotensin II inhibits activity of human organic anion transporter 3 through activation of protein kinase Calpha: accelerating endocytosis of the transporter. Eur J Pharmacol. 2009;627:49-55.
16. Li S, Duan P, You G. Regulation of human organic anion transporter 3 by peptide hormone bradykinin. J Pharmacol Exp Ther. 2010;333:970-5.
17. Barros SA, Srimaroeng C, Perry JL, Walden R, Dembla-Rajpal N, Sweet DH, et al. Activation of protein kinase Czeta increases OAT1 (SLC22A6)- and OAT3 (SLC22A8)-mediated transport. J Biol Chem. 2009;284:2672-9.
18. Eraly SA, Hamilton BA, Nigam SK. Organic anion and cation transporters occur in pairs of similar and similarly expressed genes. Biochem Biophys Res Commun. 2003;300:333-42. (Pubitemid 38379656)
19. Li T, Walsh JR, Ghishan FK, Bai L. Molecular cloning and characterization of a human urate transporter (hURAT1) gene promoter. Biochim Biophys Acta. 2004;1681:53-8. (Pubitemid 39550371)
20. Lazzaro D, De Simone V, De Magistris L, Lehtonen E, Cortese R. LFB1 and LFB3 homeoproteins are sequentially expressed during kidney development. Development. 1992;114:469-79.
21. Maher JM, Slitt AL, Callaghan TN, Cheng X, Cheung C, Gonzalez FJ, et al. Alterations in transporter expression in liver, kidney, and duodenum after targeted disruption of the transcription factor HNF1alpha. Biochem Pharmacol. 2006;72:512-22. (Pubitemid 44061742)
22. Ji L, Masuda S, Saito H, Inui K. Down-regulation of rat organic cation transporter rOCT2 by 5/6 nephrectomy. Kidney Int. 2002;62:514-24. (Pubitemid 34779762)
23. Monica Torres A, Mac Laughlin M, Muller A, Brandoni A, Anzai N, Endou H. Altered renal elimination of organic anions in rats with chronic renal failure. Biochim Biophys Acta. 2005;1740:29-37. (Pubitemid 40692695)
24. Naud J, Michaud J, Beauchemin S, Hebert MJ, Roger M, Lefrancois S, et al. Effects of chronic renal failure on kidney drug transporters and cytochrome P450 in rats. Drug Metab Dispos. 2011;39:1363-9.
25. Kwon O, Hong SM, Blouch K. Alteration in renal organic anion transporter 1 after ischemia/reperfusion in cadaveric renal allografts. J Histochem Cytochem. 2007;55:575-84. (Pubitemid 46791940)
26. Kwon O, Wang WW, Miller S. Renal organic anion transporter 1 is maldistributed and diminishes in proximal tubule cells but increases in vasculature after ischemia and reperfusion. Am J Physiol Renal Physiol. 2008;295:F1807-16.
27. Schneider R, Sauvant C, Betz B, Otremba M, Fischer D, Holzinger H, et al. Downregulation of organic anion transporters OAT1 and OAT3 correlates with impaired secretion of para-aminohippurate after ischemic acute renal failure in rats. Am J Physiol Renal Physiol. 2007;292:F1599-605. (Pubitemid 46701888)
28. Matsuzaki T, Watanabe H, Yoshitome K, Morisaki T, Hamada A, Nonoguchi H, et al. Downregulation of organic anion transporters in rat kidney under ischemia/reperfusion-induced acute renal failure. Kidney Int. 2007;71:539-47. (Pubitemid 46398686)
29. Di Giusto G, Anzai N, Endou H, Torres AM. Oat5 and NaDC1 protein abundance in kidney and urine after renal ischemic reperfusion injury. J Histochem Cytochem. 2009;57:17-27.
30. Kunin M, Holtzman EJ, Melnikov S, Dinour D. Urinary organic anion transporter protein profiles in AKI. Nephrol Dial Transplant. 2012;27:1387-95.
31. Astorga B, Wunz TM, Morales M, Wright SH, Pelis RM. Differences in the substrate binding regions of renal organic anion transporters 1 (OAT1) and 3 (OAT3). Am J Physiol Renal Physiol. 2011;301:F378-86.
32. Rodiger M, Zhang X, Ugele B, Gersdorff N, Wright SH, Burckhardt G, et al. Organic anion transporter 3 (OAT3) and renal transport of the metal chelator 2,3-dimercapto-1-propanesulfonic acid (DMPS). Can J Physiol Pharmacol. 2010;88:141-6.
33. Makino T, Okajima K, Uebayashi R, Ohtake N, Inoue K, Mizukami H. 3-Monoglucuronyl-glycyrrhretinic acid is a substrate of organic anion transporters expressed in tubular epithelial cells and plays important roles in licorice-induced pseudoaldosteronism by inhibiting 11beta-hydroxysteroid dehydrogenase 2. J Pharmacol Exp Ther. 2012;342:297-304.
34. Uwai Y, Iwamoto K. Transport of aminopterin by human organic anion transporters hOAT1 and hOAT3: comparison with methotrexate. Drug Metab Pharmacokinet. 2010;25:163-9.
35. Chiba S, Ikawa T, Takeshita H, Ichiba K, Sagi M, Mukai T, et al. Interactions of human organic anion transporter 1 (hOAT1) with substances associated with forensic toxicology. Leg Med (Tokyo). 2011;13:180-5.
36. Ahn SY, Jamshidi N, Mo ML, Wu W, Eraly SA, Dnyanmote A, et al. Linkage of organic anion transporter-1 to metabolic pathways through integrated "omics"-driven network and functional analysis. J Biol Chem. 2011;286:31522-31.
37. Bakhiya N, Arlt VM, Bahn A, Burckhardt G, Phillips DH, Glatt H. Molecular evidence for an involvement of organic anion transporters (OATs) in aristolochic acid nephropathy. Toxicology. 2009;264:74-9.
38. Babu E, Takeda M, Nishida R, Noshiro-Kofuji R, Yoshida M, Ueda S, et al. Interactions of human organic anion transporters with aristolochic acids. J Pharmacol Sci. 2010;113:192-6.
39. Xue X, Gong LK, Maeda K, Luan Y, Qi XM, Sugiyama Y, et al. Critical role of organic anion transporters 1 and 3 in kidney accumulation and toxicity of aristolochic acid I. Mol Pharm. 2011;8:2183-92.
40. Dickman KG, Sweet DH, Bonala R, Ray T, Wu A. Physiological and molecular characterization of aristolochic acid transport by the kidney. J Pharmacol Exp Ther. 2011;338:588-97.
41. Zeng Y, Zhang R, Wu J, Liu M, Peng W, Yu X, et al. Organic anion transporter 1 (OAT1) involved in renal cell transport of aristolochic acid I. Hum Exp Toxicol 2012; 31: 759-70.
42. Zhu Y, Meng Q, Wang C, Liu Q, Sun H, Kaku T, et al. Organic anion transporters involved in the excretion of bestatin in the kidney. Peptides. 2012;33:265-71.
43. Wong CC, Barron D, Orfila C, Dionisi F, Krajcsi P, Williamson G. Interaction of hydroxycinnamic acids and their conjugates with organic anion transporters and ATP-binding cassette transporters. Mol Nutr Food Res. 2011;55:979-88.
44. Uwai Y, Ozeki Y, Isaka T, Honjo H, Iwamoto K. Inhibitory effect of caffeic acid on human organic anion transporters hOAT1 and hOAT3: a novel candidate for food-drug interaction. Drug Metab Pharmacokinet. 2011;26:486-93.
45. Zhang J, Wang C, Liu Q, Meng Q, Cang J, Sun H, et al. Pharmacokinetic interaction between JBP485 and cephalexin in rats. Drug Metab Dispos. 2010;38:930-8.
46. Wong CC, Botting NP, Orfila C, Al-Maharik N, Williamson G. Flavonoid conjugates interact with organic anion transporters (OATs) and attenuate cytotoxicity of adefovir mediated by organic anion transporter 1 (OAT1/SLC22A6). Biochem Pharmacol. 2011;81:942-9.
47. Wang L, Sweet DH. Potential for food-drug interactions by dietary phenolic acids on human organic anion transporters 1 (SLC22A6), 3 (SLC22A8), and 4 (SLC22A11). Biochem Pharmacol. 2012;84:1088-95.
48. Larsen M, Holm R, Jensen KG, Sveigaard C, Brodin B, Nielsen CU. 5-Hydroxy-L-tryptophan alters gaboxadol pharmacokinetics in rats: involvement of PAT1 and rOat1 in gaboxadol absorption and elimination. Eur J Pharm Sci. 2010;39:68-75.
49. Wikoff WR, Nagle MA, Kouznetsova VL, Tsigelny IF, Nigam SK. Untargeted metabolomics identifies enterobiome metabolites and putative uremic toxins as substrates of organic anion transporter 1 (Oat1). J Proteome Res. 2011;10:2842-51.
50. Wang L, Sweet DH. Active hydrophilic components of the medicinal herb salvia miltiorrhiza (Danshen) potently inhibit organic anion transporters 1 (Slc22a6) and 3 (Slc22a8). Evid Based Complement Alternat Med. 2012;2012:(Article ID: 872458).
51. Uwai Y, Honjo H, Iwamoto K. Inhibitory effect of selective cyclooxygenase-2 inhibitor lumiracoxib on human organic anion transporters hOAT1 and hOAT3. Drug Metab Pharmacokinet. 2010;25:450-5.
52. Choi MK, Jin QR, Choi YL, Ahn SH, Bae MA, Song IS. Inhibitory effects of ketoconazole and rifampin on OAT1 and OATP1B1 transport activities: considerations on drug-drug interactions. Biopharm Drug Dispos. 2011;32:175-84.
53. Elsby R, Fox L, Stresser D, Layton M, Butters C, Sharma P, et al. In vitro risk assessment of AZD9056 perpetrating a transporter-mediated drug-drug interaction with methotrexate. Eur J Pharm Sci. 2011;43:41-9.
54. Fork C, Bauer T, Golz S, Geerts A, Weiland J, Del Turco D, et al. OAT2 catalyses efflux of glutamate and uptake of orotic acid. Biochem J. 2011;436:305-12.
55. Sato M, Mamada H, Anzai N, Shirasaka Y, Nakanishi T, Tamai I. Renal secretion of uric acid by organic anion transporter 2 (OAT2/SLC22A7) in human. Biol Pharm Bull. 2010;33:498-503.
56. Lai Y, Sampson KE, Balogh LM, Brayman TG, Cox SR, Adams WJ, et al. Preclinical and clinical evidence for the collaborative transport and renal secretion of an oxazolidinone antibiotic by organic anion transporter 3 (OAT3/SLC22A8) and multidrug and toxin extrusion protein 1 (MATE1/SLC47A1). J Pharmacol Exp Ther. 2010;334:936-44.
57. Schnabolk GW, Gupta B, Mulgaonkar A, Kulkarni M, Sweet DH. Organic anion transporter 6 (Slc22a20) specificity and Sertoli cell-specific expression provide new insight on potential endogenous roles. J Pharmacol Exp Ther. 2010;334:927-35.
58. Maeda A, Tsuruoka S, Ushijima K, Kanai Y, Endou H, Saito K, et al. Drug interaction between celecoxib and methotrexate in organic anion transporter 3-transfected renal cells and in rats in vivo. Eur J Pharmacol. 2010;640:168-71.
59. Miyajima M, Kusuhara H, Fujishima M, Adachi Y, Sugiyama Y. Organic anion transporter 3 mediates the efflux transport of an amphipathic organic anion, dehydroepiandrosterone sulfate, across the blood-brain barrier in mice. Drug Metab Dispos. 2011;39:814-9.
60. Yang CH, Glover KP, Han X. Characterization of cellular uptake of perfluorooctanoate via organic anion-transporting polypeptide 1A2, organic anion transporter 4, and urate transporter 1 for their potential roles in mediating human renal reabsorption of perfluorocarboxylates. Toxicol Sci. 2010;117:294-302.
61. Shin HJ, Takeda M, Enomoto A, Fujimura M, Miyazaki H, Anzai N, et al. Interactions of urate transporter URAT1 in human kidney with uricosuric drugs. Nephrology (Carlton). 2011;16:156-62.
62. Uetake D, Ohno I, Ichida K, Yamaguchi Y, Saikawa H, Endou H, et al. Effect of fenofibrate on uric acid metabolism and urate transporter 1. Intern Med. 2010;49:89-94.
63. Nakamura M, Anzai N, Jutabha P, Sato H, Sakurai H, Ichida K. Concentration-dependent inhibitory effect of irbesartan on renal uric acid transporters. J Pharmacol Sci. 2010;114:115-8.
64. Miura D, Anzai N, Jutabha P, Chanluang S, He X, Fukutomi T, et al. Human urate transporter 1 (hURAT1) mediates the transport of orotate. J Physiol Sci. 2011;61:253-7.
65. Wempe MF, Jutabha P, Quade B, Iwen TJ, Frick MM, Ross IR, et al. Developing potent human uric acid transporter 1 (hURAT1) inhibitors. J Med Chem. 2011;54:2701-13.
66. Ljubojevic M, Herak-Kramberger CM, Hagos Y, Bahn A, Endou H, Burckhardt G, et al. Rat renal cortical OAT1 and OAT3 exhibit gender differences determined by both androgen stimulation and estrogen inhibition. Am J Physiol Renal Physiol. 2004;287:F124-38. (Pubitemid 38780592)
67. Aslamkhan AG, Han YH, Yang XP, Zalups RK, Pritchard JB. Human renal organic anion transporter 1-dependent uptake and toxicity of mercuric-thiol conjugates in Madin-Darby canine kidney cells. Mol Pharmacol. 2003;63:590-6. (Pubitemid 36297329)
68. Torres AM, Dnyanmote AV, Bush KT, Wu W, Nigam SK. Deletion of multispecific organic anion transporter Oat1/Slc22a6 protects against mercury-induced kidney injury. J Biol Chem. 2011;286:26391-5.
69. Wojcikowski K, Johnson DW, Gobe G. Medicinal herbal extracts - renal friend or foe? Part one: the toxicities of medicinal herbs. Nephrology (Carlton). 2004;9:313-8. (Pubitemid 39576935)
70. Debelle FD, Vanherweghem JL, Nortier JL. Aristolochic acid nephropathy: a worldwide problem. Kidney Int. 2008;74:158-69. (Pubitemid 351915079)
71. Lebeau C, Debelle FD, Arlt VM, Pozdzik A, De Prez EG, Phillips DH, et al. Early proximal tubule injury in experimental aristolochic acid nephropathy: functional and histological studies. Nephrol Dial Transplant. 2005;20:2321-32. (Pubitemid 41548855)
72. Pozdzik AA, Salmon IJ, Debelle FD, Decaestecker C, Van den Branden C, Verbeelen D, et al. Aristolochic acid induces proximal tubule apoptosis and epithelial to mesenchymal transformation. Kidney Int. 2008;73:595-607. (Pubitemid 351264108)
73. Sato N, Takahashi D, Chen SM, Tsuchiya R, Mukoyama T, Yamagata S, et al. Acute nephrotoxicity of aristolochic acids in mice. J Pharm Pharmacol. 2004;56:221-9. (Pubitemid 38232752)
74. Shibutani S, Dong H, Suzuki N, Ueda S, Miller F, Grollman AP. Selective toxicity of aristolochic acids I and II. Drug Metab Dispos. 2007;35:1217-22. (Pubitemid 46956445)
75. Lou Y, Li J, Lu Y, Wang X, Jiao R, Wang S, et al. Aristolochic acid-induced destruction of organic ion transporters and fatty acid metabolic disorder in the kidney of rats. Toxicol Lett. 2011;201:72-9.
76. Russell W, Duthie G. Plant secondary metabolites and gut health: the case for phenolic acids. Proc Nutr Soc. 2011;70:389-96.
77. Fleschhut J, Kratzer F, Rechkemmer G, Kulling SE. Stability and biotransformation of various dietary anthocyanins in vitro. Eur J Nutr. 2006;45:7-18. (Pubitemid 43221279)
78. Rababah TM, Ereifej KI, Esoh RB, Al-u'datt MH, Alrababah MA, Yang W. Antioxidant activities, total phenolics and HPLC analyses of the phenolic compounds of extracts from common Mediterranean plants. Nat Prod Res. 2011;25:596-605.
79. Whitley AC, Sweet DH, Walle T. The dietary polyphenol ellagic acid is a potent inhibitor of hOAT1. Drug Metab Dispos. 2005;33:1097-100. (Pubitemid 41043750)
80. Saito H. Pathophysiological regulation of renal SLC22A organic ion transporters in acute kidney injury: pharmacological and toxicological implications. Pharmacol Ther. 2009;125:79-91.
81. Sun H, Frassetto L, Benet LZ. Effects of renal failure on drug transport and metabolism. Pharmacol Ther. 2006;109:1-11. (Pubitemid 41740811)
82. Enomoto A, Endou H. Roles of organic anion transporters (OATs) and a urate transporter (URAT1) in the pathophysiology of human disease. Clin Exp Nephrol. 2005;9:195-205. (Pubitemid 41414118)
83. Shobeiri N, Adams MA, Holden RM. Vascular calcification in animal models of CKD: a review. Am J Nephrol. 2010;31:471-81.
84. Cihlar T, Lin DC, Pritchard JB, Fuller MD, Mendel DB, Sweet DH. The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. Mol Pharmacol. 1999;56:570-80. (Pubitemid 29406884)
85. Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA. 2005;294:813-8. (Pubitemid 41175724)
86. Corrigan G, Ramaswamy D, Kwon O, Sommer FG, Alfrey EJ, Dafoe DC, et al. PAH extraction and estimation of plasma flow in human postischemic acute renal failure. Am J Physiol. 1999;277:F312-8.
87. Sauvant C, Holzinger H, Gekle M. Prostaglandin E2 inhibits its own renal transport by downregulation of organic anion transporters rOAT1 and rOAT3. J Am Soc Nephrol. 2006;17:46-53.
88. Myers SI, Wang L, Liu F, Bartula LL. Suprarenal aortic clamping and reperfusion decreases medullary and cortical blood flow by decreased endogenous renal nitric oxide and PGE2 synthesis. J Vasc Surg. 2005;42:524-31. (Pubitemid 41323846)
89. Tokuyama H, Hayashi K, Matsuda H, Kubota E, Honda M, Okubo K, et al. Stenosis-dependent role of nitric oxide and prostaglandins in chronic renal ischemia. Am J Physiol Renal Physiol. 2002;282:F859-65.
90. Schneider R, Meusel M, Renker S, Bauer C, Holzinger H, Roeder M, et al. Low-dose indomethacin after ischemic acute kidney injury prevents downregulation of Oat1/3 and improves renal outcome. Am J Physiol Renal Physiol. 2009;297:F1614-21.
91. Hocherl K, Schmidt C, Bucher M. COX-2 inhibition attenuates endotoxin-induced downregulation of organic anion transporters in the rat renal cortex. Kidney Int. 2009;75:373-80.
92. Welling PG, Dean S, Selen A, Kendall MJ, Wise R. Probenecid: an unexplained effect on cephalosporin pharmacology. Br J Clin Pharmacol. 1979;8:491-5. (Pubitemid 10194835)
93. Bourke RS, Chheda G, Bremer A, Watanabe O, Tower DB. Inhibition of renal tubular transport of methotrexate by probenecid. Cancer Res. 1975;35:110-6.
94. Jaehde U, Sorgel F, Reiter A, Sigl G, Naber KG, Schunack W. Effect of probenecid on the distribution and elimination of ciprofloxacin in humans. Clin Pharmacol Ther. 1995;58:532-41.
95. Honari J, Blair AD, Cutler RE. Effects of probenecid on furosemide kinetics and natriuresis in man. Clin Pharmacol Ther. 1977;22:395-401. (Pubitemid 8193461)
96. Mulgaonkar A, Venitz J, Sweet DH. Fluoroquinolone disposition: identification of the contribution of renal secretory and reabsorptive drug transporters. Expert Opin Drug Metab Toxicol. 2012;8:553-69.
97. Cutler MJ, Urquhart BL, Velenosi TJ, Meyer Zu Schwabedissen HE, Dresser GK, Leake BF, et al. In vitro and in vivo assessment of renal drug transporters in the disposition of mesna and dimesna. J Clin Pharmacol. 2012;52:530-42.
98. Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin Pharmacol Ther. 2003;73:538-44. (Pubitemid 37249124)
99. Nakagomi-Hagihara R, Nakai D, Tokui T. Inhibition of human organic anion transporter 3 mediated pravastatin transport by gemfibrozil and the metabolites in humans. Xenobiotica. 2007;37:416-26. (Pubitemid 46572887)
100. Yuan H, Feng B, Yu Y, Chupka J, Zheng JY, Heath TG, et al. Renal organic anion transporter-mediated drug-drug interaction between gemcabene and quinapril. J Pharmacol Exp Ther. 2009;330:191-7.
101. Giacomini KM, Huang SM, Tweedie DJ. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9:215-36.
102. Bhatnagar V, Xu G, Hamilton BA, Truong DM, Eraly SA, Wu W, et al. Analyses of 5′ regulatory region polymorphisms in human SLC22A6 (OAT1) and SLC22A8 (OAT3). J Hum Genet. 2006;51:575-80. (Pubitemid 43954308)
103. Shima JE, Komori T, Taylor TR, Stryke D, Kawamoto M, Johns SJ, et al. Genetic variants of human organic anion transporter 4 demonstrate altered transport of endogenous substrates. Am J Physiol Renal Physiol. 2010;299:F767-75.
104. Zhou F, Zhu L, Cui PH, Church WB, Murray M. Functional characterization of nonsynonymous single nucleotide polymorphisms in the human organic anion transporter 4 (hOAT4). Br J Pharmacol. 2010;159:419-27.
105. Rizwan AN, Burckhardt G. Organic anion transporters of the SLC22 family: biopharmaceutical, physiological, and pathological roles. Pharm Res. 2007;24:450-70. (Pubitemid 46295167)
106. Han YF, Fan XH, Wang XJ, Sun K, Xue H, Li WJ, et al. Association of intergenic polymorphism of organic anion transporter 1 and 3 genes with hypertension and blood pressure response to hydrochlorothiazide. Am J Hypertens. 2011;24:340-6.
107. Sakurai Y, Motohashi H, Ueo H, Masuda S, Saito H, Okuda M, et al. Expression levels of renal organic anion transporters (OATs) and their correlation with anionic drug excretion in patients with renal diseases. Pharm Res. 2004;21:61-7. (Pubitemid 38122293)
108. Sweet DH, Eraly SA, Vaughn DA, Bush KT, Nigam SK. Organic anion and cation transporter expression and function during embryonic kidney development and in organ culture models. Kidney Int. 2006;69:837-45.